All In Biotech

Drug Trial Radar · NCT00641914

Inhaled Steroid Treatment as Regular Therapy in Early Asthma

Inhaled Steroid Treatment As Regular Therapy in Early Asthma. A Study on the Effect of Early Intervention With Long-Term Inhaled Budesonide (Pulmicort Turbuhaler ® ) in Newly Diagnosed Asthma.

Last checked: Nov 19, 2026Latest source record: Mar 25, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 6,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

6,800

Planned (sponsor's estimate)

Start

Oct 1996

Primary completion

Feb 2003

Study completion Feb 2003

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Mar 24, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A study of the effect of the early treatment with Pulmicort of newly diagnosed asthma. Patients will receive either Pulmicort or a non-active treatment for three years. Neither patients or investigators will be aware of the treatment received. After three years of treatment all patients will receive Pulmicort for 2 further years.

Conditions

  • Asthma

Interventions

  • budesonideDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Severe asthma related events (SARE) (part A); post-bronchodilator FEV1 % of predicted normal (part B)Time frame: At week 6 and12, and every 3 months thereafter

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.